nodes	percent_of_prediction	percent_of_DWPC	metapath
Naratriptan—HTR1D—meninx—melanoma	0.0887	0.601	CbGeAlD
Naratriptan—HTR1B—blood vessel—melanoma	0.0104	0.0704	CbGeAlD
Naratriptan—HTR1D—blood vessel—melanoma	0.0101	0.0682	CbGeAlD
Naratriptan—HTR1F—head—melanoma	0.00767	0.0519	CbGeAlD
Naratriptan—MAOA—neck—melanoma	0.00549	0.0372	CbGeAlD
Naratriptan—HTR1D—eye—melanoma	0.00536	0.0363	CbGeAlD
Naratriptan—MAOA—retina—melanoma	0.00404	0.0274	CbGeAlD
Naratriptan—MAOA—mammalian vulva—melanoma	0.00324	0.0219	CbGeAlD
Naratriptan—HTR1B—head—melanoma	0.00314	0.0213	CbGeAlD
Naratriptan—HTR1D—head—melanoma	0.00304	0.0206	CbGeAlD
Naratriptan—HTR1A—head—melanoma	0.00254	0.0172	CbGeAlD
Naratriptan—MAOA—head—melanoma	0.00232	0.0157	CbGeAlD
Naratriptan—Bone pain—Docetaxel—melanoma	0.00214	0.00371	CcSEcCtD
Naratriptan—Infection—Vemurafenib—melanoma	0.00213	0.00371	CcSEcCtD
Naratriptan—Liver function test abnormal—Carmustine—melanoma	0.00213	0.00371	CcSEcCtD
Naratriptan—Inflammation—Docetaxel—melanoma	0.00211	0.00366	CcSEcCtD
Naratriptan—Nervous system disorder—Vemurafenib—melanoma	0.00211	0.00366	CcSEcCtD
Naratriptan—Skin disorder—Vemurafenib—melanoma	0.00209	0.00362	CcSEcCtD
Naratriptan—Dehydration—Temozolomide—melanoma	0.00208	0.00361	CcSEcCtD
Naratriptan—Pneumonia—Bleomycin—melanoma	0.00205	0.00357	CcSEcCtD
Naratriptan—Dry skin—Temozolomide—melanoma	0.00205	0.00356	CcSEcCtD
Naratriptan—Blood pressure increased—Docetaxel—melanoma	0.00205	0.00355	CcSEcCtD
Naratriptan—Acute coronary syndrome—Bleomycin—melanoma	0.00201	0.00349	CcSEcCtD
Naratriptan—Hypotension—Vemurafenib—melanoma	0.00201	0.00349	CcSEcCtD
Naratriptan—Myocardial infarction—Bleomycin—melanoma	0.002	0.00347	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00196	0.0034	CcSEcCtD
Naratriptan—Fluid retention—Docetaxel—melanoma	0.00194	0.00337	CcSEcCtD
Naratriptan—Pneumonia—Dactinomycin—melanoma	0.00191	0.00333	CcSEcCtD
Naratriptan—Oesophagitis—Docetaxel—melanoma	0.00187	0.00325	CcSEcCtD
Naratriptan—Bronchitis—Temozolomide—melanoma	0.00186	0.00323	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Vemurafenib—melanoma	0.00186	0.00322	CcSEcCtD
Naratriptan—Fatigue—Vemurafenib—melanoma	0.00185	0.00322	CcSEcCtD
Naratriptan—Haemoglobin—Bleomycin—melanoma	0.00184	0.0032	CcSEcCtD
Naratriptan—Constipation—Vemurafenib—melanoma	0.00184	0.00319	CcSEcCtD
Naratriptan—Haemorrhage—Bleomycin—melanoma	0.00183	0.00318	CcSEcCtD
Naratriptan—Hypoaesthesia—Bleomycin—melanoma	0.00182	0.00317	CcSEcCtD
Naratriptan—Hyperglycaemia—Carmustine—melanoma	0.0018	0.00313	CcSEcCtD
Naratriptan—Pneumonia—Carmustine—melanoma	0.00179	0.00311	CcSEcCtD
Naratriptan—Pollakiuria—Temozolomide—melanoma	0.00178	0.0031	CcSEcCtD
Naratriptan—Depression—Carmustine—melanoma	0.00178	0.00309	CcSEcCtD
Naratriptan—Photosensitivity reaction—Temozolomide—melanoma	0.00176	0.00306	CcSEcCtD
Naratriptan—Neuropathy peripheral—Carmustine—melanoma	0.00175	0.00303	CcSEcCtD
Naratriptan—Hyperglycaemia—Temozolomide—melanoma	0.00174	0.00303	CcSEcCtD
Naratriptan—Pneumonia—Temozolomide—melanoma	0.00173	0.00301	CcSEcCtD
Naratriptan—Depression—Temozolomide—melanoma	0.00172	0.00298	CcSEcCtD
Naratriptan—Body temperature increased—Vemurafenib—melanoma	0.0017	0.00295	CcSEcCtD
Naratriptan—Neuropathy peripheral—Temozolomide—melanoma	0.00169	0.00293	CcSEcCtD
Naratriptan—Swelling—Docetaxel—melanoma	0.00168	0.00292	CcSEcCtD
Naratriptan—Chills—Bleomycin—melanoma	0.00164	0.00286	CcSEcCtD
Naratriptan—MAOA—lymph node—melanoma	0.00162	0.011	CbGeAlD
Naratriptan—Alopecia—Bleomycin—melanoma	0.00162	0.00281	CcSEcCtD
Naratriptan—Sinusitis—Temozolomide—melanoma	0.00162	0.00281	CcSEcCtD
Naratriptan—Haemoglobin—Carmustine—melanoma	0.00161	0.00279	CcSEcCtD
Naratriptan—Haemorrhage—Carmustine—melanoma	0.0016	0.00278	CcSEcCtD
Naratriptan—Erythema—Bleomycin—melanoma	0.0016	0.00277	CcSEcCtD
Naratriptan—Hypoaesthesia—Carmustine—melanoma	0.00159	0.00276	CcSEcCtD
Naratriptan—Hallucination—Carmustine—melanoma	0.00159	0.00276	CcSEcCtD
Naratriptan—Hypersensitivity—Vemurafenib—melanoma	0.00158	0.00275	CcSEcCtD
Naratriptan—Atrial fibrillation—Docetaxel—melanoma	0.00157	0.00272	CcSEcCtD
Naratriptan—Haemoglobin—Temozolomide—melanoma	0.00155	0.0027	CcSEcCtD
Naratriptan—Haemorrhage—Temozolomide—melanoma	0.00155	0.00268	CcSEcCtD
Naratriptan—Asthenia—Vemurafenib—melanoma	0.00154	0.00268	CcSEcCtD
Naratriptan—Hypoaesthesia—Temozolomide—melanoma	0.00154	0.00267	CcSEcCtD
Naratriptan—Hallucination—Temozolomide—melanoma	0.00154	0.00267	CcSEcCtD
Naratriptan—Chills—Dactinomycin—melanoma	0.00153	0.00266	CcSEcCtD
Naratriptan—Pruritus—Vemurafenib—melanoma	0.00152	0.00264	CcSEcCtD
Naratriptan—Alopecia—Dactinomycin—melanoma	0.00151	0.00262	CcSEcCtD
Naratriptan—Erythema—Dactinomycin—melanoma	0.00149	0.00258	CcSEcCtD
Naratriptan—Ill-defined disorder—Bleomycin—melanoma	0.00148	0.00257	CcSEcCtD
Naratriptan—Anaemia—Bleomycin—melanoma	0.00147	0.00256	CcSEcCtD
Naratriptan—Diarrhoea—Vemurafenib—melanoma	0.00147	0.00255	CcSEcCtD
Naratriptan—Migraine—Docetaxel—melanoma	0.00146	0.00254	CcSEcCtD
Naratriptan—Tinnitus—Temozolomide—melanoma	0.00144	0.0025	CcSEcCtD
Naratriptan—Malaise—Bleomycin—melanoma	0.00144	0.0025	CcSEcCtD
Naratriptan—Cardiac disorder—Temozolomide—melanoma	0.00143	0.00249	CcSEcCtD
Naratriptan—Arrhythmia—Carmustine—melanoma	0.00143	0.00248	CcSEcCtD
Naratriptan—Dizziness—Vemurafenib—melanoma	0.00142	0.00247	CcSEcCtD
Naratriptan—Alopecia—Carmustine—melanoma	0.00141	0.00245	CcSEcCtD
Naratriptan—Angiopathy—Temozolomide—melanoma	0.0014	0.00244	CcSEcCtD
Naratriptan—Immune system disorder—Temozolomide—melanoma	0.0014	0.00242	CcSEcCtD
Naratriptan—Erythema—Carmustine—melanoma	0.00139	0.00242	CcSEcCtD
Naratriptan—Cough—Bleomycin—melanoma	0.00139	0.00242	CcSEcCtD
Naratriptan—Chills—Temozolomide—melanoma	0.00139	0.00241	CcSEcCtD
Naratriptan—Dehydration—Docetaxel—melanoma	0.00138	0.0024	CcSEcCtD
Naratriptan—Ill-defined disorder—Dactinomycin—melanoma	0.00138	0.0024	CcSEcCtD
Naratriptan—Anaemia—Dactinomycin—melanoma	0.00138	0.00239	CcSEcCtD
Naratriptan—Liver function test abnormal—Docetaxel—melanoma	0.00137	0.00238	CcSEcCtD
Naratriptan—Vomiting—Vemurafenib—melanoma	0.00137	0.00237	CcSEcCtD
Naratriptan—Alopecia—Temozolomide—melanoma	0.00137	0.00237	CcSEcCtD
Naratriptan—Dry skin—Docetaxel—melanoma	0.00136	0.00237	CcSEcCtD
Naratriptan—Myalgia—Bleomycin—melanoma	0.00136	0.00236	CcSEcCtD
Naratriptan—Rash—Vemurafenib—melanoma	0.00135	0.00235	CcSEcCtD
Naratriptan—Dermatitis—Vemurafenib—melanoma	0.00135	0.00235	CcSEcCtD
Naratriptan—Headache—Vemurafenib—melanoma	0.00135	0.00234	CcSEcCtD
Naratriptan—Erythema—Temozolomide—melanoma	0.00135	0.00234	CcSEcCtD
Naratriptan—Discomfort—Bleomycin—melanoma	0.00134	0.00233	CcSEcCtD
Naratriptan—Malaise—Dactinomycin—melanoma	0.00134	0.00233	CcSEcCtD
Naratriptan—Cramp muscle—Docetaxel—melanoma	0.00134	0.00232	CcSEcCtD
Naratriptan—Confusional state—Bleomycin—melanoma	0.00131	0.00228	CcSEcCtD
Naratriptan—Vision blurred—Carmustine—melanoma	0.00131	0.00228	CcSEcCtD
Naratriptan—Tremor—Carmustine—melanoma	0.0013	0.00227	CcSEcCtD
Naratriptan—Anaphylactic shock—Bleomycin—melanoma	0.0013	0.00226	CcSEcCtD
Naratriptan—Oedema—Bleomycin—melanoma	0.0013	0.00226	CcSEcCtD
Naratriptan—Infection—Bleomycin—melanoma	0.00129	0.00225	CcSEcCtD
Naratriptan—Anaemia—Carmustine—melanoma	0.00129	0.00223	CcSEcCtD
Naratriptan—Agitation—Carmustine—melanoma	0.00128	0.00222	CcSEcCtD
Naratriptan—Nausea—Vemurafenib—melanoma	0.00128	0.00222	CcSEcCtD
Naratriptan—Thrombocytopenia—Bleomycin—melanoma	0.00127	0.00221	CcSEcCtD
Naratriptan—Vision blurred—Temozolomide—melanoma	0.00127	0.0022	CcSEcCtD
Naratriptan—Myalgia—Dactinomycin—melanoma	0.00127	0.0022	CcSEcCtD
Naratriptan—Tremor—Temozolomide—melanoma	0.00126	0.00219	CcSEcCtD
Naratriptan—Discomfort—Dactinomycin—melanoma	0.00125	0.00217	CcSEcCtD
Naratriptan—Angina pectoris—Docetaxel—melanoma	0.00125	0.00217	CcSEcCtD
Naratriptan—Ill-defined disorder—Temozolomide—melanoma	0.00125	0.00217	CcSEcCtD
Naratriptan—Anaemia—Temozolomide—melanoma	0.00124	0.00216	CcSEcCtD
Naratriptan—Agitation—Temozolomide—melanoma	0.00124	0.00215	CcSEcCtD
Naratriptan—Hypotension—Bleomycin—melanoma	0.00122	0.00211	CcSEcCtD
Naratriptan—Oedema—Dactinomycin—melanoma	0.00121	0.00211	CcSEcCtD
Naratriptan—Malaise—Temozolomide—melanoma	0.00121	0.00211	CcSEcCtD
Naratriptan—Vertigo—Temozolomide—melanoma	0.00121	0.0021	CcSEcCtD
Naratriptan—Convulsion—Carmustine—melanoma	0.00121	0.0021	CcSEcCtD
Naratriptan—Infection—Dactinomycin—melanoma	0.00121	0.00209	CcSEcCtD
Naratriptan—Palpitations—Temozolomide—melanoma	0.00119	0.00206	CcSEcCtD
Naratriptan—Thrombocytopenia—Dactinomycin—melanoma	0.00119	0.00206	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Bleomycin—melanoma	0.00119	0.00206	CcSEcCtD
Naratriptan—Myalgia—Carmustine—melanoma	0.00119	0.00206	CcSEcCtD
Naratriptan—Anxiety—Carmustine—melanoma	0.00118	0.00205	CcSEcCtD
Naratriptan—Cough—Temozolomide—melanoma	0.00117	0.00204	CcSEcCtD
Naratriptan—Paraesthesia—Bleomycin—melanoma	0.00117	0.00203	CcSEcCtD
Naratriptan—Convulsion—Temozolomide—melanoma	0.00117	0.00202	CcSEcCtD
Naratriptan—Dyspnoea—Bleomycin—melanoma	0.00116	0.00202	CcSEcCtD
Naratriptan—Pneumonia—Docetaxel—melanoma	0.00115	0.002	CcSEcCtD
Naratriptan—Confusional state—Carmustine—melanoma	0.00115	0.00199	CcSEcCtD
Naratriptan—Myalgia—Temozolomide—melanoma	0.00115	0.00199	CcSEcCtD
Naratriptan—Arthralgia—Temozolomide—melanoma	0.00115	0.00199	CcSEcCtD
Naratriptan—Anxiety—Temozolomide—melanoma	0.00114	0.00198	CcSEcCtD
Naratriptan—Oedema—Carmustine—melanoma	0.00114	0.00197	CcSEcCtD
Naratriptan—Discomfort—Temozolomide—melanoma	0.00113	0.00197	CcSEcCtD
Naratriptan—Infection—Carmustine—melanoma	0.00113	0.00196	CcSEcCtD
Naratriptan—Acute coronary syndrome—Docetaxel—melanoma	0.00113	0.00196	CcSEcCtD
Naratriptan—Neuropathy peripheral—Docetaxel—melanoma	0.00112	0.00195	CcSEcCtD
Naratriptan—Myocardial infarction—Docetaxel—melanoma	0.00112	0.00195	CcSEcCtD
Naratriptan—Dry mouth—Temozolomide—melanoma	0.00112	0.00195	CcSEcCtD
Naratriptan—Pain—Bleomycin—melanoma	0.00111	0.00193	CcSEcCtD
Naratriptan—Thrombocytopenia—Carmustine—melanoma	0.00111	0.00193	CcSEcCtD
Naratriptan—Confusional state—Temozolomide—melanoma	0.00111	0.00192	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Dactinomycin—melanoma	0.00111	0.00192	CcSEcCtD
Naratriptan—Anaphylactic shock—Temozolomide—melanoma	0.0011	0.00191	CcSEcCtD
Naratriptan—Oedema—Temozolomide—melanoma	0.0011	0.00191	CcSEcCtD
Naratriptan—Infection—Temozolomide—melanoma	0.00109	0.00189	CcSEcCtD
Naratriptan—Nervous system disorder—Temozolomide—melanoma	0.00108	0.00187	CcSEcCtD
Naratriptan—Thrombocytopenia—Temozolomide—melanoma	0.00108	0.00187	CcSEcCtD
Naratriptan—Feeling abnormal—Bleomycin—melanoma	0.00107	0.00186	CcSEcCtD
Naratriptan—Skin disorder—Temozolomide—melanoma	0.00107	0.00185	CcSEcCtD
Naratriptan—Hypotension—Carmustine—melanoma	0.00106	0.00184	CcSEcCtD
Naratriptan—Hyperhidrosis—Temozolomide—melanoma	0.00106	0.00184	CcSEcCtD
Naratriptan—Fatigue—Dactinomycin—melanoma	0.00105	0.00182	CcSEcCtD
Naratriptan—Pain—Dactinomycin—melanoma	0.00104	0.0018	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Carmustine—melanoma	0.00104	0.0018	CcSEcCtD
Naratriptan—Urticaria—Bleomycin—melanoma	0.00103	0.0018	CcSEcCtD
Naratriptan—Haemoglobin—Docetaxel—melanoma	0.00103	0.00179	CcSEcCtD
Naratriptan—Body temperature increased—Bleomycin—melanoma	0.00103	0.00179	CcSEcCtD
Naratriptan—Haemorrhage—Docetaxel—melanoma	0.00103	0.00179	CcSEcCtD
Naratriptan—Hypoaesthesia—Docetaxel—melanoma	0.00102	0.00178	CcSEcCtD
Naratriptan—Paraesthesia—Carmustine—melanoma	0.00102	0.00177	CcSEcCtD
Naratriptan—Dyspnoea—Carmustine—melanoma	0.00101	0.00176	CcSEcCtD
Naratriptan—Somnolence—Carmustine—melanoma	0.00101	0.00175	CcSEcCtD
Naratriptan—Feeling abnormal—Dactinomycin—melanoma	0.001	0.00174	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Temozolomide—melanoma	0.001	0.00174	CcSEcCtD
Naratriptan—Paraesthesia—Temozolomide—melanoma	0.000986	0.00171	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Carmustine—melanoma	0.000981	0.0017	CcSEcCtD
Naratriptan—Dyspnoea—Temozolomide—melanoma	0.000979	0.0017	CcSEcCtD
Naratriptan—Somnolence—Temozolomide—melanoma	0.000976	0.0017	CcSEcCtD
Naratriptan—Constipation—Carmustine—melanoma	0.000972	0.00169	CcSEcCtD
Naratriptan—Pain—Carmustine—melanoma	0.000972	0.00169	CcSEcCtD
Naratriptan—Body temperature increased—Dactinomycin—melanoma	0.00096	0.00167	CcSEcCtD
Naratriptan—Hypersensitivity—Bleomycin—melanoma	0.000959	0.00167	CcSEcCtD
Naratriptan—Cardiac disorder—Docetaxel—melanoma	0.000954	0.00166	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Temozolomide—melanoma	0.000948	0.00165	CcSEcCtD
Naratriptan—Fatigue—Temozolomide—melanoma	0.000947	0.00164	CcSEcCtD
Naratriptan—Pain—Temozolomide—melanoma	0.000939	0.00163	CcSEcCtD
Naratriptan—Constipation—Temozolomide—melanoma	0.000939	0.00163	CcSEcCtD
Naratriptan—Feeling abnormal—Carmustine—melanoma	0.000936	0.00163	CcSEcCtD
Naratriptan—Asthenia—Bleomycin—melanoma	0.000934	0.00162	CcSEcCtD
Naratriptan—Angiopathy—Docetaxel—melanoma	0.000933	0.00162	CcSEcCtD
Naratriptan—Immune system disorder—Docetaxel—melanoma	0.000929	0.00161	CcSEcCtD
Naratriptan—Chills—Docetaxel—melanoma	0.000922	0.0016	CcSEcCtD
Naratriptan—Pruritus—Bleomycin—melanoma	0.000921	0.0016	CcSEcCtD
Naratriptan—Arrhythmia—Docetaxel—melanoma	0.000918	0.00159	CcSEcCtD
Naratriptan—Alopecia—Docetaxel—melanoma	0.000908	0.00158	CcSEcCtD
Naratriptan—Feeling abnormal—Temozolomide—melanoma	0.000905	0.00157	CcSEcCtD
Naratriptan—Body temperature increased—Carmustine—melanoma	0.000898	0.00156	CcSEcCtD
Naratriptan—Erythema—Docetaxel—melanoma	0.000895	0.00155	CcSEcCtD
Naratriptan—Hypersensitivity—Dactinomycin—melanoma	0.000895	0.00155	CcSEcCtD
Naratriptan—Urticaria—Temozolomide—melanoma	0.000872	0.00151	CcSEcCtD
Naratriptan—Asthenia—Dactinomycin—melanoma	0.000871	0.00151	CcSEcCtD
Naratriptan—Body temperature increased—Temozolomide—melanoma	0.000868	0.00151	CcSEcCtD
Naratriptan—Muscle spasms—Docetaxel—melanoma	0.00086	0.00149	CcSEcCtD
Naratriptan—Hypersensitivity—Carmustine—melanoma	0.000837	0.00145	CcSEcCtD
Naratriptan—Diarrhoea—Dactinomycin—melanoma	0.000831	0.00144	CcSEcCtD
Naratriptan—Vomiting—Bleomycin—melanoma	0.000828	0.00144	CcSEcCtD
Naratriptan—Anaemia—Docetaxel—melanoma	0.000827	0.00144	CcSEcCtD
Naratriptan—Rash—Bleomycin—melanoma	0.000821	0.00143	CcSEcCtD
Naratriptan—Dermatitis—Bleomycin—melanoma	0.00082	0.00142	CcSEcCtD
Naratriptan—Asthenia—Carmustine—melanoma	0.000815	0.00142	CcSEcCtD
Naratriptan—Hypersensitivity—Temozolomide—melanoma	0.000809	0.00141	CcSEcCtD
Naratriptan—Syncope—Docetaxel—melanoma	0.000802	0.00139	CcSEcCtD
Naratriptan—Palpitations—Docetaxel—melanoma	0.000791	0.00137	CcSEcCtD
Naratriptan—Asthenia—Temozolomide—melanoma	0.000788	0.00137	CcSEcCtD
Naratriptan—Loss of consciousness—Docetaxel—melanoma	0.000787	0.00137	CcSEcCtD
Naratriptan—Cough—Docetaxel—melanoma	0.000781	0.00136	CcSEcCtD
Naratriptan—Diarrhoea—Carmustine—melanoma	0.000778	0.00135	CcSEcCtD
Naratriptan—Pruritus—Temozolomide—melanoma	0.000777	0.00135	CcSEcCtD
Naratriptan—Convulsion—Docetaxel—melanoma	0.000775	0.00135	CcSEcCtD
Naratriptan—Nausea—Bleomycin—melanoma	0.000773	0.00134	CcSEcCtD
Naratriptan—Vomiting—Dactinomycin—melanoma	0.000772	0.00134	CcSEcCtD
Naratriptan—Rash—Dactinomycin—melanoma	0.000766	0.00133	CcSEcCtD
Naratriptan—Myalgia—Docetaxel—melanoma	0.000762	0.00132	CcSEcCtD
Naratriptan—Arthralgia—Docetaxel—melanoma	0.000762	0.00132	CcSEcCtD
Naratriptan—Dizziness—Carmustine—melanoma	0.000751	0.0013	CcSEcCtD
Naratriptan—Diarrhoea—Temozolomide—melanoma	0.000751	0.0013	CcSEcCtD
Naratriptan—Dry mouth—Docetaxel—melanoma	0.000745	0.00129	CcSEcCtD
Naratriptan—Confusional state—Docetaxel—melanoma	0.000736	0.00128	CcSEcCtD
Naratriptan—Anaphylactic shock—Docetaxel—melanoma	0.00073	0.00127	CcSEcCtD
Naratriptan—Oedema—Docetaxel—melanoma	0.00073	0.00127	CcSEcCtD
Naratriptan—Dizziness—Temozolomide—melanoma	0.000726	0.00126	CcSEcCtD
Naratriptan—Infection—Docetaxel—melanoma	0.000726	0.00126	CcSEcCtD
Naratriptan—Vomiting—Carmustine—melanoma	0.000723	0.00125	CcSEcCtD
Naratriptan—Nausea—Dactinomycin—melanoma	0.000721	0.00125	CcSEcCtD
Naratriptan—Shock—Docetaxel—melanoma	0.000719	0.00125	CcSEcCtD
Naratriptan—Rash—Carmustine—melanoma	0.000717	0.00124	CcSEcCtD
Naratriptan—Nervous system disorder—Docetaxel—melanoma	0.000716	0.00124	CcSEcCtD
Naratriptan—Dermatitis—Carmustine—melanoma	0.000716	0.00124	CcSEcCtD
Naratriptan—Thrombocytopenia—Docetaxel—melanoma	0.000715	0.00124	CcSEcCtD
Naratriptan—Headache—Carmustine—melanoma	0.000712	0.00124	CcSEcCtD
Naratriptan—Skin disorder—Docetaxel—melanoma	0.000709	0.00123	CcSEcCtD
Naratriptan—Vomiting—Temozolomide—melanoma	0.000698	0.00121	CcSEcCtD
Naratriptan—Rash—Temozolomide—melanoma	0.000692	0.0012	CcSEcCtD
Naratriptan—Dermatitis—Temozolomide—melanoma	0.000692	0.0012	CcSEcCtD
Naratriptan—Headache—Temozolomide—melanoma	0.000688	0.00119	CcSEcCtD
Naratriptan—Hypotension—Docetaxel—melanoma	0.000682	0.00119	CcSEcCtD
Naratriptan—Nausea—Carmustine—melanoma	0.000675	0.00117	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Docetaxel—melanoma	0.000665	0.00116	CcSEcCtD
Naratriptan—Paraesthesia—Docetaxel—melanoma	0.000656	0.00114	CcSEcCtD
Naratriptan—Nausea—Temozolomide—melanoma	0.000652	0.00113	CcSEcCtD
Naratriptan—Dyspnoea—Docetaxel—melanoma	0.000651	0.00113	CcSEcCtD
Naratriptan—Somnolence—Docetaxel—melanoma	0.000649	0.00113	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Docetaxel—melanoma	0.000631	0.00109	CcSEcCtD
Naratriptan—Fatigue—Docetaxel—melanoma	0.00063	0.00109	CcSEcCtD
Naratriptan—Pain—Docetaxel—melanoma	0.000625	0.00108	CcSEcCtD
Naratriptan—Constipation—Docetaxel—melanoma	0.000625	0.00108	CcSEcCtD
Naratriptan—Feeling abnormal—Docetaxel—melanoma	0.000602	0.00105	CcSEcCtD
Naratriptan—Body temperature increased—Docetaxel—melanoma	0.000577	0.001	CcSEcCtD
Naratriptan—Hypersensitivity—Docetaxel—melanoma	0.000538	0.000934	CcSEcCtD
Naratriptan—Asthenia—Docetaxel—melanoma	0.000524	0.00091	CcSEcCtD
Naratriptan—Pruritus—Docetaxel—melanoma	0.000517	0.000897	CcSEcCtD
Naratriptan—Diarrhoea—Docetaxel—melanoma	0.0005	0.000868	CcSEcCtD
Naratriptan—Dizziness—Docetaxel—melanoma	0.000483	0.000839	CcSEcCtD
Naratriptan—Vomiting—Docetaxel—melanoma	0.000464	0.000806	CcSEcCtD
Naratriptan—Rash—Docetaxel—melanoma	0.00046	0.0008	CcSEcCtD
Naratriptan—Dermatitis—Docetaxel—melanoma	0.00046	0.000799	CcSEcCtD
Naratriptan—Headache—Docetaxel—melanoma	0.000458	0.000794	CcSEcCtD
Naratriptan—Nausea—Docetaxel—melanoma	0.000434	0.000753	CcSEcCtD
Naratriptan—HTR1D—GPCR downstream signaling—IL2—melanoma	6.63e-05	0.00024	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—GNAQ—melanoma	6.63e-05	0.00024	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—FGF1—melanoma	6.59e-05	0.000239	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CSF2—melanoma	6.59e-05	0.000239	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—E2F1—melanoma	6.59e-05	0.000238	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—PIK3CB—melanoma	6.56e-05	0.000237	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PDGFRA—melanoma	6.52e-05	0.000236	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—IL2—melanoma	6.5e-05	0.000235	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—ITGB3—melanoma	6.46e-05	0.000234	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PRKCA—melanoma	6.46e-05	0.000234	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—E2F1—melanoma	6.45e-05	0.000233	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—PIK3CB—melanoma	6.42e-05	0.000232	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PDGFRA—melanoma	6.39e-05	0.000231	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—PIK3CG—melanoma	6.39e-05	0.000231	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—SPP1—melanoma	6.33e-05	0.000229	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—ITGB3—melanoma	6.32e-05	0.000229	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PRKCA—melanoma	6.32e-05	0.000229	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MAP2K2—melanoma	6.31e-05	0.000228	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—CXCL8—melanoma	6.3e-05	0.000228	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—PIK3CA—melanoma	6.25e-05	0.000226	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—SYK—melanoma	6.23e-05	0.000225	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—MDM2—melanoma	6.23e-05	0.000225	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—SPP1—melanoma	6.2e-05	0.000224	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—PIK3CD—melanoma	6.18e-05	0.000224	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MAP2K2—melanoma	6.18e-05	0.000224	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—CXCL8—melanoma	6.17e-05	0.000223	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—ERBB2—melanoma	6.14e-05	0.000222	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—NGFR—melanoma	6.12e-05	0.000221	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—ITGAV—melanoma	6.12e-05	0.000221	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—AKT3—melanoma	6.12e-05	0.000221	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—PIK3CB—melanoma	6.06e-05	0.000219	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—IL2—melanoma	6.02e-05	0.000218	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—TERT—melanoma	6e-05	0.000217	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—RAC1—melanoma	5.99e-05	0.000217	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—IL2—melanoma	5.9e-05	0.000213	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—TERT—melanoma	5.88e-05	0.000213	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—RAC1—melanoma	5.86e-05	0.000212	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CXCL8—melanoma	5.82e-05	0.000211	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—HRAS—melanoma	5.79e-05	0.000209	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—HIF1A—melanoma	5.74e-05	0.000208	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CDKN1B—melanoma	5.69e-05	0.000206	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—SOCS1—melanoma	5.66e-05	0.000205	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—MAP2K1—melanoma	5.65e-05	0.000204	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—S100B—melanoma	5.65e-05	0.000204	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—AKT1—melanoma	5.63e-05	0.000203	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—HIF1A—melanoma	5.62e-05	0.000203	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—PIK3CD—melanoma	5.61e-05	0.000203	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CASP3—melanoma	5.57e-05	0.000202	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—IL2—melanoma	5.57e-05	0.000201	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—IL6—melanoma	5.54e-05	0.0002	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—KDR—melanoma	5.49e-05	0.000199	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CCND1—melanoma	5.43e-05	0.000196	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—ERBB4—melanoma	5.4e-05	0.000195	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—PIK3CB—melanoma	5.39e-05	0.000195	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—KDR—melanoma	5.38e-05	0.000194	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CTNNB1—melanoma	5.37e-05	0.000194	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CDKN2B—melanoma	5.36e-05	0.000194	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PIK3CG—melanoma	5.31e-05	0.000192	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—FN1—melanoma	5.28e-05	0.000191	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—MMP9—melanoma	5.27e-05	0.000191	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CDKN1A—melanoma	5.25e-05	0.00019	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—PTEN—melanoma	5.24e-05	0.000189	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—NFKB1—melanoma	5.21e-05	0.000188	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CD86—melanoma	5.18e-05	0.000187	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—CXCL8—melanoma	5.18e-05	0.000187	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—FN1—melanoma	5.17e-05	0.000187	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—NOTCH1—melanoma	5.17e-05	0.000187	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—EDN1—melanoma	5.14e-05	0.000186	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PPARG—melanoma	5.12e-05	0.000185	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—AKT1—melanoma	5.11e-05	0.000185	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CD80—melanoma	5.07e-05	0.000183	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—NOTCH1—melanoma	5.06e-05	0.000183	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—APC—melanoma	5.06e-05	0.000183	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PIK3CG—melanoma	5.06e-05	0.000183	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—KIT—melanoma	5.06e-05	0.000183	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—NRAS—melanoma	5.06e-05	0.000183	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—FGF1—melanoma	5.02e-05	0.000182	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CSF2—melanoma	5.02e-05	0.000182	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—EGF—melanoma	5e-05	0.000181	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CD80—melanoma	4.96e-05	0.000179	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—KIT—melanoma	4.95e-05	0.000179	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—APC—melanoma	4.95e-05	0.000179	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PIK3CG—melanoma	4.95e-05	0.000179	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—NRAS—melanoma	4.95e-05	0.000179	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—IL2—melanoma	4.95e-05	0.000179	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—E2F1—melanoma	4.92e-05	0.000178	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—EGF—melanoma	4.89e-05	0.000177	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—PIK3CB—melanoma	4.89e-05	0.000177	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PDGFRA—melanoma	4.87e-05	0.000176	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—MAPK3—melanoma	4.84e-05	0.000175	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—ITGB3—melanoma	4.82e-05	0.000174	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PRKCA—melanoma	4.82e-05	0.000174	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—BRAF—melanoma	4.75e-05	0.000172	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—MAPK3—melanoma	4.74e-05	0.000172	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—VEGFA—melanoma	4.73e-05	0.000171	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—SPP1—melanoma	4.72e-05	0.000171	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MAP2K2—melanoma	4.71e-05	0.00017	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—CXCL8—melanoma	4.7e-05	0.00017	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—STAT3—melanoma	4.68e-05	0.000169	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—NRAS—melanoma	4.67e-05	0.000169	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PIK3CD—melanoma	4.67e-05	0.000169	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—BRAF—melanoma	4.65e-05	0.000168	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—IGF1—melanoma	4.63e-05	0.000167	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—MAPK1—melanoma	4.61e-05	0.000167	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—EGFR—melanoma	4.61e-05	0.000167	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—ALB—melanoma	4.61e-05	0.000167	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—IGF1—melanoma	4.53e-05	0.000164	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—MAPK1—melanoma	4.51e-05	0.000163	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—EGFR—melanoma	4.51e-05	0.000163	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—IL2—melanoma	4.49e-05	0.000163	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—TERT—melanoma	4.48e-05	0.000162	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MAP2K1—melanoma	4.48e-05	0.000162	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—MAPK3—melanoma	4.47e-05	0.000162	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—RAC1—melanoma	4.47e-05	0.000161	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PIK3CD—melanoma	4.45e-05	0.000161	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—PIK3CA—melanoma	4.4e-05	0.000159	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MAP2K1—melanoma	4.38e-05	0.000158	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PIK3CD—melanoma	4.35e-05	0.000157	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—KRAS—melanoma	4.35e-05	0.000157	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—MYC—melanoma	4.35e-05	0.000157	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—PIK3CA—melanoma	4.31e-05	0.000156	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—HIF1A—melanoma	4.28e-05	0.000155	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—KRAS—melanoma	4.26e-05	0.000154	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—MAPK1—melanoma	4.26e-05	0.000154	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—FGF2—melanoma	4.26e-05	0.000154	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—EGFR—melanoma	4.26e-05	0.000154	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—FGF2—melanoma	4.17e-05	0.000151	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—KDR—melanoma	4.1e-05	0.000148	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PIK3CB—melanoma	4.07e-05	0.000147	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PTGS2—melanoma	4.03e-05	0.000146	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—KRAS—melanoma	4.02e-05	0.000145	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—PIK3CA—melanoma	4e-05	0.000145	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MDM2—melanoma	3.98e-05	0.000144	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—FN1—melanoma	3.94e-05	0.000143	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—ERBB2—melanoma	3.93e-05	0.000142	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—PIK3CA—melanoma	3.92e-05	0.000142	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MDM2—melanoma	3.9e-05	0.000141	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PIK3CB—melanoma	3.88e-05	0.00014	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—NOTCH1—melanoma	3.86e-05	0.00014	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—ERBB2—melanoma	3.85e-05	0.000139	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PIK3CB—melanoma	3.79e-05	0.000137	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CD80—melanoma	3.78e-05	0.000137	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—KIT—melanoma	3.77e-05	0.000136	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—APC—melanoma	3.77e-05	0.000136	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PIK3CG—melanoma	3.77e-05	0.000136	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—NRAS—melanoma	3.77e-05	0.000136	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—EGF—melanoma	3.73e-05	0.000135	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CXCL8—melanoma	3.72e-05	0.000135	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—HRAS—melanoma	3.7e-05	0.000134	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—PIK3CA—melanoma	3.69e-05	0.000134	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CXCL8—melanoma	3.65e-05	0.000132	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CDKN1B—melanoma	3.64e-05	0.000132	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—HRAS—melanoma	3.62e-05	0.000131	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—MAPK3—melanoma	3.61e-05	0.000131	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—AKT1—melanoma	3.6e-05	0.00013	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—TP53—melanoma	3.57e-05	0.000129	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CASP3—melanoma	3.56e-05	0.000129	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CDKN1B—melanoma	3.56e-05	0.000129	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—IL2—melanoma	3.56e-05	0.000129	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—BRAF—melanoma	3.55e-05	0.000128	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—IL6—melanoma	3.54e-05	0.000128	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—AKT1—melanoma	3.52e-05	0.000127	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PTEN—melanoma	3.51e-05	0.000127	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CASP3—melanoma	3.49e-05	0.000126	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—IL2—melanoma	3.48e-05	0.000126	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CCND1—melanoma	3.47e-05	0.000125	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—IL6—melanoma	3.47e-05	0.000125	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—IGF1—melanoma	3.45e-05	0.000125	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—MAPK1—melanoma	3.44e-05	0.000124	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—EGFR—melanoma	3.44e-05	0.000124	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CTNNB1—melanoma	3.44e-05	0.000124	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—HRAS—melanoma	3.42e-05	0.000124	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CCND1—melanoma	3.4e-05	0.000123	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MMP9—melanoma	3.37e-05	0.000122	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CTNNB1—melanoma	3.36e-05	0.000122	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CDKN1A—melanoma	3.36e-05	0.000121	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PTEN—melanoma	3.35e-05	0.000121	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MAP2K1—melanoma	3.34e-05	0.000121	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—NFKB1—melanoma	3.33e-05	0.000121	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PIK3CD—melanoma	3.32e-05	0.00012	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MMP9—melanoma	3.3e-05	0.000119	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CDKN1A—melanoma	3.29e-05	0.000119	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—PIK3CA—melanoma	3.28e-05	0.000119	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PTEN—melanoma	3.28e-05	0.000119	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—IL6—melanoma	3.27e-05	0.000118	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—AKT1—melanoma	3.27e-05	0.000118	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—NFKB1—melanoma	3.26e-05	0.000118	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—KRAS—melanoma	3.25e-05	0.000117	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—AKT1—melanoma	3.2e-05	0.000116	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—FGF2—melanoma	3.18e-05	0.000115	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—VEGFA—melanoma	3.02e-05	0.000109	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—AKT1—melanoma	3.02e-05	0.000109	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—STAT3—melanoma	2.99e-05	0.000108	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—NRAS—melanoma	2.99e-05	0.000108	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—PIK3CA—melanoma	2.98e-05	0.000108	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MDM2—melanoma	2.97e-05	0.000107	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—VEGFA—melanoma	2.96e-05	0.000107	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—STAT3—melanoma	2.93e-05	0.000106	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—ERBB2—melanoma	2.93e-05	0.000106	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—NRAS—melanoma	2.93e-05	0.000106	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PIK3CB—melanoma	2.89e-05	0.000105	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MAPK3—melanoma	2.86e-05	0.000103	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MAPK3—melanoma	2.8e-05	0.000101	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MYC—melanoma	2.78e-05	0.000101	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CXCL8—melanoma	2.78e-05	0.0001	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—HRAS—melanoma	2.76e-05	9.98e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MYC—melanoma	2.72e-05	9.86e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MAPK1—melanoma	2.72e-05	9.85e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—EGFR—melanoma	2.72e-05	9.84e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CDKN1B—melanoma	2.71e-05	9.81e-05	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—AKT1—melanoma	2.68e-05	9.71e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MAPK1—melanoma	2.67e-05	9.64e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—EGFR—melanoma	2.67e-05	9.64e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CASP3—melanoma	2.66e-05	9.62e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—IL2—melanoma	2.65e-05	9.6e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—IL6—melanoma	2.64e-05	9.55e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CCND1—melanoma	2.59e-05	9.36e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—KRAS—melanoma	2.57e-05	9.3e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CTNNB1—melanoma	2.56e-05	9.27e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—KRAS—melanoma	2.52e-05	9.11e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MMP9—melanoma	2.51e-05	9.09e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CDKN1A—melanoma	2.5e-05	9.05e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PTEN—melanoma	2.5e-05	9.03e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—NFKB1—melanoma	2.49e-05	8.99e-05	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PIK3CA—melanoma	2.48e-05	8.97e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—AKT1—melanoma	2.44e-05	8.81e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PIK3CA—melanoma	2.36e-05	8.54e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PIK3CA—melanoma	2.31e-05	8.37e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—TP53—melanoma	2.29e-05	8.27e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—VEGFA—melanoma	2.26e-05	8.16e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—TP53—melanoma	2.24e-05	8.09e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—STAT3—melanoma	2.23e-05	8.08e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—NRAS—melanoma	2.23e-05	8.06e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—HRAS—melanoma	2.19e-05	7.91e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—HRAS—melanoma	2.14e-05	7.74e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MAPK3—melanoma	2.13e-05	7.72e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—IL6—melanoma	2.09e-05	7.57e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MYC—melanoma	2.08e-05	7.51e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—IL6—melanoma	2.05e-05	7.41e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MAPK1—melanoma	2.03e-05	7.34e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—EGFR—melanoma	2.03e-05	7.34e-05	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—AKT1—melanoma	2.03e-05	7.32e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—AKT1—melanoma	1.93e-05	6.98e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—KRAS—melanoma	1.92e-05	6.94e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—AKT1—melanoma	1.89e-05	6.83e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PIK3CA—melanoma	1.76e-05	6.37e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—TP53—melanoma	1.7e-05	6.17e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—HRAS—melanoma	1.63e-05	5.9e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—IL6—melanoma	1.56e-05	5.64e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—AKT1—melanoma	1.44e-05	5.21e-05	CbGpPWpGaD
